Six Democratic candidates vying for New Jersey’s governorship spoke directly to voters at the first debate of the season ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Newark, N.J. Mayor Ras Baraka says there can be disagreements about immigrants, but everyone must respect and follow the U.S. Constitution.

Thus, we will focus primarily on the therapeutic targeting of the major RAS effector pathways, in addition to several essential co-opted pathways, as reviewed in the next section. MEK/CDK4 PD ...

Hympavzi’s entry to market marked a significant advancement in treatment options available for patients with the rare disease, becoming the first approved anti-tissue factor pathway inhibitor. In the ...

The studies suggest that mutant KRAS signals predominantly through the rapidly accelerating fibrosarcoma (RAF) effector pathway in pancreatic ductal adenocarcinoma (PDAC) models, with its ...

Ras Al Khaimah Tourism Development Authority (RAKTDA) has reported its strongest year on record, welcoming 1.28 million overnight arrivals in 2024, a significant milestone that highlights the ...